Graphical summary. Credit score: American Journal of Physiology-Cell Physiology (2024). DOI: 10.1152/ajpcell.00528.2024
Pulmonary fibrosis is a uncommon, persistent illness that causes scarring within the lungs, making respiration tough for individuals who undergo with it. And, as College of South Florida pulmonologist Dr. Jose Herazo-Maya is aware of all too effectively, it’s usually irreversible.
However when Herazo-Maya, director of the Ubben Middle for Pulmonary Fibrosis Analysis and an affiliate professor on the USF Well being Morsani Faculty of Drugs, started learning sufferers who developed pulmonary fibrosis after contracting extreme circumstances of COVID-19, he and his analysis crew seen one thing unusual.
The sufferers’ lungs acquired higher.
“The importance of this finding is that pulmonary fibrosis after COVID-19 tends to resolve, while in idiopathic pulmonary fibrosis (IPF) it always progresses,” Herazo-Maya mentioned. “We need to learn about the factors associated with pulmonary fibrosis resolution and apply it to non-resolving forms of pulmonary fibrosis.”
The crew’s findings are revealed in print this month within the American Journal of Physiology-Cell Physiology in a paper titled “Convergent and Divergent Immune Aberrations in COVID-19, post-COVID-19-Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis.” Herazo-Maya is the senior writer.
One key query is whether or not researchers can apply what they’ve realized from these COVID-19 sufferers to sufferers who’ve IPF, the commonest type of pulmonary fibrosis.
Herazo-Maya believes they will, and he’s learning the consequences of extreme COVID on individuals who subsequently developed pulmonary fibrosis and making use of that data to develop new remedies to enhance survival in sufferers with each situations.
Since COVID-19 began, Herazo-Maya and his crew have been investigating the similarities between irregular ranges of genes within the blood of sufferers with IPF and COVID. These new findings construct on scientists’ earlier understanding by addressing the identification of the immune cells the place the genes are activated or deactivated and their relationship within the two ailments.
“In the present manuscript, which is a follow up of our initial work, we wanted to study the cellular origin of these genes in COVID-19 and IPF,” Herazo-Maya mentioned. “This time, we also studied patients with post-COVID-19-interstitial lung disease—that is, pulmonary fibrosis that happens as a result of COVID-19. To achieve this goal, we used single-cell RNA sequencing, a novel technique that allows us to study the entire human genome in each single cell from patients.”
The brand new findings describe how sure genes in monocytes—white blood cells within the immune system—orchestrate suppression of T cells within the blood, resulting in elevated threat of dying in COVID-19. The research concerned a suppressor cell referred to as 7-Gene-M-MDSC—brief for monocytic myeloid derived suppressive cells.
“What this means is that 7-Gene-M-MDSC are associated with increased risk of COVID-19 mortality, but if you survive severe COVID-19 and end up having pulmonary fibrosis as a result, the pulmonary fibrosis is self-limited and not progressive,” mentioned lead writer, Bochra Tourki, a member of Herazo-Maya’s crew. “We think this is because of the disappearance of the 7-Gene-M-MDSC and the resurgence of T cell responses.”
T cells are a sort of white blood cell that assist the immune system struggle germs and push back illness. However why does pulmonary fibrosis in post-COVID-19 are likely to resolve whereas it progresses in folks with IPF who aren’t sick from COVID-19?
“Both diseases are caused by injury to alveolar epithelial cells in the lungs,” Herazo-Maya defined. “In the case of COVID-19, the injury is viral and acute and in the case of IPF, the injury is unknown but repetitive and chronic—so that may explain the different patterns of pulmonary fibrosis progression. What we found in this study were the key immune elements (cells and genes) that may explain resolution versus progression of pulmonary fibrosis.”
IPF impacts the tissue surrounding the air sacs, or alveoli, within the lungs. This situation develops when lung tissue turns into thick and stiff for causes nonetheless unknown and results in the irreversible lung scarring that makes respiration tough.
The brand new analysis is a comply with up of Herazo-Maya’s earlier work in pinpointing genes to foretell lung fibrosis outcomes. The first purpose of his ongoing analysis is to determine genes that predict outcomes for folks with lung fibrosis, as a result of by concentrating on these genes, researchers may have the ability to develop new remedies to assist enhance survival charges.
“We believe that the opportunity is to modulate the expression of genes identified in this study as a way to treat acute COVID-19, post-COVID-19 pulmonary fibrosis and IPF,” he mentioned.
This raises the chance that blocking the expression of genes in monocytes or rising the expression of sure genes in T cells might flip a illness that at all times progresses right into a type of pulmonary fibrosis that may be handled.
“In the future,” Herazo-Maya mentioned, “strategies aiming at modulating the cells that cause these genes to change may lead to novel therapies that could improve COVID-19 survival.”
Extra data:
Bochra Tourki et al, Convergent and divergent immune aberrations in COVID-19, post-COVID-19-interstitial lung illness, and idiopathic pulmonary fibrosis, American Journal of Physiology-Cell Physiology (2024). DOI: 10.1152/ajpcell.00528.2024
Offered by
College of South Florida
Quotation:
COVID-19 sufferers with pulmonary fibrosis present surprising lung enchancment (2025, January 23)
retrieved 23 January 2025
from https://medicalxpress.com/information/2025-01-covid-patients-pulmonary-fibrosis-unexpected.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
